A Study of Tirzepatide in Participants With Impaired Liver Function

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-22

Study Completion Date

2020-09-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

NCT04407234

Overweight Obesity Diabetes Mellitus, Type 2

COMPLETED PHASE1

Study of Tirzepatide in Healthy Participants

NCT04311424

Healthy

COMPLETED PHASE1

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

NCT04081337

Obesity

COMPLETED PHASE1

A Study of Tirzepatide (LY3298176) in Healthy Participants

NCT03375463

Healthy

COMPLETED PHASE1

A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

NCT07299084

Diabetes Mellitus, Type 2 Overweight Obesity

NOT_YET_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Hepatic Function

Participants with normal hepatic function received single subcutaneous dose of 5 milligrams (mg) tirzepatide.

Group Type ACTIVE_COMPARATOR

Tirzepatide

Intervention Type DRUG

Administered SC

Mild Hepatic Impairment

Participants with mild hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.

Group Type EXPERIMENTAL

Tirzepatide

Intervention Type DRUG

Administered SC

Moderate Hepatic Impairment

Participants with moderate hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.

Group Type EXPERIMENTAL

Tirzepatide

Intervention Type DRUG

Administered SC

Severe Hepatic Impairment

Participants with severe hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.

Group Type EXPERIMENTAL

Tirzepatide

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tirzepatide

Administered SC

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY3298176

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All Participants:

* Women of childbearing potential are excluded from the study.
* Women not of childbearing potential may participate and include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis; or postmenopausal
* Are between the body mass index (BMI) of 19.0 and 40.0 kilograms per meter squared (kg/m²), inclusive, at screening

Healthy Participants:

\- Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal liver function

Participants with Impaired Liver Function:

* Males or females with chronic mild, moderate and severe liver impairment, assessed by Child-Pugh scoring
* Have type 2 diabetes mellitus (T2DM) controlled with diet or exercise alone or on stable doses of metformin for at least 8 weeks
* Have a hemoglobin A1c (HbA1c) ≥6.0% and ≤11.0% at screening

Exclusion Criteria

All Participants:

* Have known allergies to tirzepatide or related compounds
* Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
* Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase or GI disorder (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors

Participants with Impaired Liver Function:

* Have hemoglobin \<8.5 grams per deciliter (g/dL)
* Have kidney function that is significantly impaired at screening
* Have taken any glucose-lowering medications other than metformin, including insulin, in the past 3 months before screening
* Have brain function impaired significantly due to liver condition

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes